R
Raul D. Santos
Researcher at University of São Paulo
Publications - 463
Citations - 21660
Raul D. Santos is an academic researcher from University of São Paulo. The author has contributed to research in topics: Familial hypercholesterolemia & Medicine. The author has an hindex of 56, co-authored 404 publications receiving 16997 citations. Previous affiliations of Raul D. Santos include Albert Einstein Hospital.
Papers
More filters
Journal ArticleDOI
Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
Pamela R.S. Silva,Cinthia E. Jannes,Theo G M Oliveira,Marcio H. Miname,Viviane Z. Rocha,Ana Paula Marte Chacra,Maria Helane Costa Gurgel,Renan Magalhães Montenegro,Carlos Roberto Martins Rodrigues Sobrinho,Annie Seixas Bello Moreira,Marcelo Heitor Vieira Assad,Marina R.C. Pinto,Mauricio Teruo Tada,Raul D. Santos,Alexandre C. Pereira,José Eduardo Krieger +15 more
TL;DR: In the population, LDL ≥230 mg/dL is a feasible criterion to indicate ICs to genetic testing, and LDL-C values had the best tradeoff between sensitivity and specificity to diagnose a mutation.
Journal ArticleDOI
Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
Pamela R.S. Silva,Cinthia E. Jannes,Julia Daher Carneiro Marsiglia,José Eduardo Krieger,Raul D. Santos,Alexandre C. Pereira +5 more
TL;DR: A high one-year incidence of CV events was found in this cascade-screening cohort of individuals enrolled in Brazil's genetic cascade screening program for Familial Hypercholesterolemia (FH), Hipercol Brasil.
Journal ArticleDOI
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report
Aurélie Thedrez,Barbara Sjouke,Maxime Passard,Simon Prampart-Fauvet,Alexis Guedon,Mickael Croyal,Geesje Dallinga-Thie,Jorge Peter,Dirk J. Blom,Milco Ciccarese,Angelo B. Cefalù,Livia Pisciotta,Raul D. Santos,Maurizio Averna,Frederick J. Raal,Paolo Pintus,Maria Laura Cossu,Kees Hovingh,Gilles Lambert +18 more
TL;DR: Overall, the effects of recombinant PCSK9, and hence of alirocumab, on LDL receptor expression and function were significantly less pronounced in ARH than in control cells.
Journal ArticleDOI
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels
Kang H. Zheng,Yannick Kaiser,Casper C. van Olden,Raul D. Santos,Jean-Louis Dasseux,Jacques Genest,Daniel Gaudet,Jan Westerink,Constance Keyserling,Hein J. Verberne,Eran Leitersdorf,Robert A. Hegele,Olivier S. Descamps,Paul N. Hopkins,Aart J. Nederveen,Erik S.G. Stroes +15 more
TL;DR: In patients with genetically determined very low HDL-cholesterol, 24 weeks of treatment with HDL mimetic CER-001 did not reduce carotid vessel wall dimensions or arterial wall inflammation, compared with placebo.
Journal ArticleDOI
Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2.
J. Wouter Jukema,Cheng-Wen Chiang,Jean Ferrières,Raul D. Santos,Juan Verdejo,David D. Waters,Michael Messig,Lisa Tarasenko +7 more
TL;DR: An analysis of the Lipid Treatment Assessment Project 2 population indicates that despite their increased cardiovascular risk, patients with diabetes or metabolic syndrome remain undertreated.